Valuation: Mesoblast Limited

Market Cap 2.7B 1.85B 1.66B 1.53B 1.39B 2.63B 173B 18.3B 7.29B 92.92B 6.94B 6.79B 294B P/E 2027 *
-57.2x
P/E 2028 * 101x
Enterprise Value 2.81B 1.92B 1.72B 1.59B 1.44B 2.73B 180B 19.01B 7.57B 96.5B 7.21B 7.06B 305B EV / Sales 2027 *
11.4x
EV / Sales 2028 * 7.77x
Free-Float
63.36%
Yield 2027 *
-
Yield 2028 * -
1 day-2.40%
1 week-3.33%
Current month-10.18%
1 month-1.46%
3 months-15.77%
6 months+1.50%
Current year-25.37%
1 week 2.02
Extreme 2.02
2.2
1 month 1.74
Extreme 1.735
2.38
Current year 1.74
Extreme 1.735
3.31
1 year 1.74
Extreme 1.735
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 23/03/2011
Director of Finance/CFO 59 17/11/2025
Chief Tech/Sci/R&D Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 69 01/01/2007
Director/Board Member 75 15/04/2013
Director/Board Member 79 06/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/8/26 Free

Director

875,000 0.0674%
17/7/26 Exercice

Founder

1,885,334 0.1456%
17/7/26 Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-3.33%-12.12%+463.89% 1.85B
+0.01%+11.10%+60.83%+70.43% 68.32B
+1.22%+9.56%+15.97%+90.23% 60.26B
+0.24%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
-2.19%-3.71%+90.94%+66.33% 33.8B
-1.77%+0.83%+46.57%-0.16% 25.96B
Average -1.15%+4.86%+51.45%+186.92% 42B
Weighted average by Cap. -0.68%+5.52%+55.00%+154.97%

Financials

2027 *2028 *
Net sales 245M 168M 151M 139M 126M 239M 15.75B 1.66B 662M 8.44B 630M 617M 26.67B 366M 251M 225M 207M 188M 356M 23.51B 2.48B 989M 12.6B 941M 921M 39.82B
Net income -34.35M -23.53M -21.1M -19.44M -17.66M -33.42M -2.21B -233M -92.76M -1.18B -88.29M -86.42M -3.74B 56.89M 38.96M 34.94M 32.2M 29.25M 55.35M 3.65B 386M 154M 1.96B 146M 143M 6.19B
Net Debt 104M 71.27M 63.91M 58.9M 53.49M 101M 6.68B 705M 281M 3.58B 267M 262M 11.32B 143M 97.99M 87.88M 80.99M 73.55M 139M 9.19B 970M 386M 4.92B 368M 360M 15.56B
Projected Income Statement - Annual - Mesoblast Limited
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
11/11/26 A$2.030 -2.40% 1,587,374
10/11/26 A$2.080 +1.96% 2,658,570
09/11/26 A$2.040 +0.49% 2,310,883
06/11/26 A$2.030 -6.45% 2,548,051
05/11/26 A$2.170 +3.33% 3,273,099
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Mesoblast Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.080AUD
Average target price
3.507AUD
Spread / Average Target
+68.59%